Compare DCO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | OGN |
|---|---|---|
| Founded | 1849 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1995 | 2020 |
| Metric | DCO | OGN |
|---|---|---|
| Price | $168.34 | $13.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $153.60 | $11.40 |
| AVG Volume (30 Days) | 288.2K | ★ 2.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.64 | 0.55 |
| Revenue | $824,730,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $7.40 | $0.45 |
| Revenue Next Year | $8.59 | $1.67 |
| P/E Ratio | $256.00 | ★ $24.54 |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $84.76 | $5.69 |
| 52 Week High | $196.63 | $13.60 |
| Indicator | DCO | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 62.74 |
| Support Level | $135.11 | $8.51 |
| Resistance Level | $168.74 | $13.60 |
| Average True Range (ATR) | 8.46 | 0.05 |
| MACD | -2.56 | -0.04 |
| Stochastic Oscillator | 24.08 | 37.23 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.